Bevacizumab-based combination therapy in a patient with pseudomyxoma peritonei

We describe a case of pseudomyxoma peritonei arising from an adenoma of the appendix in a 58-year-old man

W. L. Sun

2009

Scholarcy highlights

  • We describe a case of pseudomyxoma peritonei arising from an adenoma of the appendix in a 58-year-old man
  • Our case suggests that modulation of tumour microenvironment and angiogenesis by bevacizumab, potentially augmented by monochemotherapy, may be beneficial in borderline tumours such as pseudomyxoma peritonei
  • Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis
  • Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
  • Prognostic value of baseline and serial carcinoembryonic antigen and carbohydrate antigen 19.9 measurements in patients with pseudomyxoma peritonei treated with cytoreduction and hyperthermic intraperitoneal chemotherapy
  • Et al Bevacizumab-based combination therapy in a patient with pseudomyxoma peritonei

Need more features? Save interactive summary cards to your Scholarcy Library.